EP2866900A2 - Composition topique apaisante a base d'extraits de paeonia et de nymphaea - Google Patents
Composition topique apaisante a base d'extraits de paeonia et de nymphaeaInfo
- Publication number
- EP2866900A2 EP2866900A2 EP13731825.9A EP13731825A EP2866900A2 EP 2866900 A2 EP2866900 A2 EP 2866900A2 EP 13731825 A EP13731825 A EP 13731825A EP 2866900 A2 EP2866900 A2 EP 2866900A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- extract
- composition
- topical
- composition according
- nymphaea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 95
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 230000000699 topical effect Effects 0.000 title claims abstract description 29
- 241000209490 Nymphaea Species 0.000 title description 13
- 241000736199 Paeonia Species 0.000 title description 13
- 240000009085 Nymphaea caerulea Species 0.000 claims abstract description 30
- 235000002195 Nymphaea caerulea Nutrition 0.000 claims abstract description 28
- 240000005001 Paeonia suffruticosa Species 0.000 claims abstract description 28
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 16
- 230000035807 sensation Effects 0.000 claims abstract description 7
- 208000003251 Pruritus Diseases 0.000 claims abstract description 5
- 230000007803 itching Effects 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims description 29
- 210000003491 skin Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 210000002615 epidermis Anatomy 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000006071 cream Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- -1 mask Substances 0.000 claims description 7
- 230000009471 action Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 239000002088 nanocapsule Substances 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 230000036642 wellbeing Effects 0.000 claims description 5
- 239000013543 active substance Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 239000002502 liposome Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 244000208874 Althaea officinalis Species 0.000 claims description 3
- 235000006576 Althaea officinalis Nutrition 0.000 claims description 3
- 235000008753 Papaver somniferum Nutrition 0.000 claims description 3
- 240000001090 Papaver somniferum Species 0.000 claims description 3
- 244000299461 Theobroma cacao Species 0.000 claims description 3
- 235000009470 Theobroma cacao Nutrition 0.000 claims description 3
- 235000001035 marshmallow Nutrition 0.000 claims description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 3
- 235000013824 polyphenols Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 240000007185 Albizia julibrissin Species 0.000 claims description 2
- 235000011468 Albizia julibrissin Nutrition 0.000 claims description 2
- 240000000662 Anethum graveolens Species 0.000 claims description 2
- 235000005881 Calendula officinalis Nutrition 0.000 claims description 2
- 244000146462 Centella asiatica Species 0.000 claims description 2
- 235000004032 Centella asiatica Nutrition 0.000 claims description 2
- 235000005206 Hibiscus Nutrition 0.000 claims description 2
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 2
- 235000010616 Hibiscus abelmoschus Nutrition 0.000 claims description 2
- 235000007185 Hibiscus lunariifolius Nutrition 0.000 claims description 2
- 244000284380 Hibiscus rosa sinensis Species 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- 240000000785 Tagetes erecta Species 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 description 16
- 108090000028 Neprilysin Proteins 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 108010049990 CD13 Antigens Proteins 0.000 description 12
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 10
- 102100022749 Aminopeptidase N Human genes 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- 240000002853 Nelumbo nucifera Species 0.000 description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000419 plant extract Substances 0.000 description 5
- 230000004224 protection Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 108010092674 Enkephalins Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- WSSJONWNBBTCMG-UHFFFAOYSA-N 2-hydroxybenzoic acid (3,3,5-trimethylcyclohexyl) ester Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C1=CC=CC=C1O WSSJONWNBBTCMG-UHFFFAOYSA-N 0.000 description 3
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 3
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 3
- 235000016428 Nymphaea stellata Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 229950009811 ubenimex Drugs 0.000 description 3
- HEOCBCNFKCOKBX-RELGSGGGSA-N (1s,2e,4r)-4,7,7-trimethyl-2-[(4-methylphenyl)methylidene]bicyclo[2.2.1]heptan-3-one Chemical compound C1=CC(C)=CC=C1\C=C/1C(=O)[C@]2(C)CC[C@H]\1C2(C)C HEOCBCNFKCOKBX-RELGSGGGSA-N 0.000 description 2
- LALVCWMSKLEQMK-UHFFFAOYSA-N 1-phenyl-3-(4-propan-2-ylphenyl)propane-1,3-dione Chemical compound C1=CC(C(C)C)=CC=C1C(=O)CC(=O)C1=CC=CC=C1 LALVCWMSKLEQMK-UHFFFAOYSA-N 0.000 description 2
- BXCRLBBIZJSWNS-UHFFFAOYSA-N 2-hydroxyethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCCO BXCRLBBIZJSWNS-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 235000019454 L-leucine Nutrition 0.000 description 2
- 235000016791 Nymphaea odorata subsp odorata Nutrition 0.000 description 2
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 2
- 235000006484 Paeonia officinalis Nutrition 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 229940087073 glycol palmitate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000929 nociceptor Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000008058 pain sensation Effects 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- CSUUDNFYSFENAE-UHFFFAOYSA-N (2-methoxyphenyl)-phenylmethanone Chemical compound COC1=CC=CC=C1C(=O)C1=CC=CC=C1 CSUUDNFYSFENAE-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ZSNLEVJATWJBLU-UHFFFAOYSA-N 2-tert-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(C(C)(C)C)(OC)C(=O)C1=CC=CC=C1 ZSNLEVJATWJBLU-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 235000019493 Macadamia oil Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000003840 Opioid Receptors Human genes 0.000 description 1
- 108090000137 Opioid Receptors Proteins 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000745768 Pluchea carolinensis Species 0.000 description 1
- 244000202052 Poncirus trifoliata Species 0.000 description 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- XNEFYCZVKIDDMS-UHFFFAOYSA-N avobenzone Chemical compound C1=CC(OC)=CC=C1C(=O)CC(=O)C1=CC=C(C(C)(C)C)C=C1 XNEFYCZVKIDDMS-UHFFFAOYSA-N 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000008278 cosmetic cream Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 229960004697 enzacamene Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000399 hydroalcoholic extract Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- PXFUDSMGEYRNNC-LURJTMIESA-N l-alanine-4-nitroanilide Chemical compound C[C@H](N)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 PXFUDSMGEYRNNC-LURJTMIESA-N 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000010469 macadamia oil Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100001085 no phototoxicity Toxicity 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- FMJSMJQBSVNSBF-UHFFFAOYSA-N octocrylene Chemical group C=1C=CC=CC=1C(=C(C#N)C(=O)OCC(CC)CCCC)C1=CC=CC=C1 FMJSMJQBSVNSBF-UHFFFAOYSA-N 0.000 description 1
- 229960000601 octocrylene Drugs 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229940057874 phenyl trimethicone Drugs 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229940048845 polyglyceryl-3 diisostearate Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000037072 sun protection Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- LINXHFKHZLOLEI-UHFFFAOYSA-N trimethyl-[phenyl-bis(trimethylsilyloxy)silyl]oxysilane Chemical compound C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)C1=CC=CC=C1 LINXHFKHZLOLEI-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Definitions
- the present invention relates to a novel cosmetic and / or dermatological composition intended to ensure the protection of the epidermis, and more particularly to a composition based on a combination of plant extracts of the genus Paeonia and Nymphaea having a soothing biological action on the skin. skin.
- the skin has several integrated layers, ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis, and each has specific properties allowing the whole to react and adapt to conditions of its environment.
- the epidermis composed mainly of keratinocytes, melanocytes and Langerhans cells, constitutes the outer layer of the skin, and plays a fundamental role in ensuring the protection and maintenance of good trophicity. That's why many compositions have been developed to protect it and improve its functions.
- the dermis consists mainly of collagen, elastin and proteoglycans, molecules synthesized by dermal fibroblasts.
- Collagen fibers provide the mechanical strength and texture of the skin
- elastin is responsible for elasticity
- proteoglycans play a major role in the structure and hydration of the skin.
- Other cells such as macrophages and leucocytes are also present in the dermis layer.
- the hypodermis which is the deepest layer of skin, contains lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects muscles, bones, and internal organs from shock.
- Enkephalins are neurotransmitters released by neurons during intense pain sensations. Their role is to inhibit the spread of pain from the nociceptors, that is to say the nerve endings in the dermis and epidermis, to the brain, responsible for the perception of pain. These are endogenous molecules that can bind to nociceptive neuron receptors and make the sensation of pain less intense, thus exerting an analgesic effect. Enkephalins can also bind to opioid receptors in the brain, which stimulates the release of dopamine by dopamine neurons and increases the sensation of pleasure.
- the peony, genus Paeonia is a perennial, herbaceous or shrubby plant according to the various known species, belonging to the family of Paeoniaceae, originating from several regions of Europe and the Far East, in particular from China. It is well known as an ornamental plant but it has been used since ancient times as a medicinal plant in Greeks as well as in traditional Chinese medicine, especially to facilitate blood circulation or for the treatment of fevers, fibroids or abscesses.
- US Patent Application 2005/106276 discloses an oral pharmaceutical composition useful in the treatment of diabetes and hyperlipidemia, comprising several plant extracts, including extracts of peony roots.
- Topical compositions for the skin comprising an extract of Paeonia suffruticosa Andrews are described in patents JP 2004269382 and JP 2006124356.
- a hydro-glycolic extract of Paeonia suffruticosa Andrews has an antioxidant activity and can be used in cosmetic anti-wrinkle compositions.
- Patent Application JP 2002121126 describes a lotion with lightening and soothing properties of skin irritations containing a root extract of Paeonia suffruticosa.
- Patent FR 2835430 discloses nanocapsules coated with lecithin limiting discomfort sensations caused by acrylamide polymers used as thickeners in cosmetic compositions; various actives can be incorporated into the nanocapsules, including an extract of Paeonia.
- the blue lotus (Nymphaea caerulea), which grows on the edges of lakes and rivers, was already used in ancient Egypt for its sweet scent and its sedative medicinal qualities. Its stems, rhizomes and seeds were consumed as a food product.
- the sacred lotus which belongs to another species, Nelumbo nucifera, different in origin and composition, contains enzymes such as methyl transferase with an anti-aging effect, as indicated in US Patent 6,468,564.
- Nymphaea especially the lotus, and water lilies contain, in all parts, water lily and nupharine, which are alkaloids, as well as other ill-defined components.
- the application WO 2006/000708 describes a composition associating a blue lotus extract and a poppy extract or a marshmallow extract, intended to combat the signs of skin aging, in particular expression lines.
- the patent application KR 20090055958 describes the combination of an extract of Poncirus trifoliate and a blue lotus extract in a cosmetic composition providing an astringent effect and a protective effect against irritation of the skin.
- the patent KR 100787782 describes the same protective effect of Nymphaea caerulea.
- compositions of the invention are distinguished in that they comprise an extract of a plant of the species Paeonia suffruticosa in association with an extract of Nymphaea caerulea in an amount effective to provide a soothing topical action of the epidermis, as well as acceptable carriers and excipients in dermatology and cosmetology.
- the subject of the present invention is therefore a novel cosmetic and / or dermatological composition based on extract of Paeonia suffruticosa in association with an extract of Nymphaea caerulea.
- Such a composition has excellent properties used in cosmetics and dermatology for the protection of the skin, more particularly to provide a soothing topical action.
- the present invention also relates to a non-therapeutic cosmetic method for providing a soothing topical action and promoting the well-being of the skin, comprising applying to the areas of the skin concerned a topical composition containing an effective amount of the combination of Paeonia suffruticosa extract and Nymphaea caerulea extract according to the present invention.
- the subject of the invention is also a dermatological pharmaceutical composition based on an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea for the protection of the epidermis and more particularly to provide a soothing topical action.
- the invention further relates to the use of an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea in combination, for the preparation of a non-therapeutic cosmetic topical composition to provide a soothing action of the epidermis.
- compositions according to the present invention are distinguished in that they comprise an extract of Paeonia suffruticosa in combination with an extract of Nymphaea caerulea in an amount effective to provide protection of the epidermis, more particularly a soothing action, as well as carriers and excipients acceptable in dermatology and cosmetology.
- topical compositions of the invention based on extract of Paeonia suffruticosa and extract of Nymphaea caerulea can be advantageously used in dermatology and cosmetology for the treatment and prevention of itching sensations and topical pain.
- the active agent is constituted by the combination of extracts of the plants Nymphaea caerulea Savigny and Paeonia suffruticosa Andrews.
- the solvent used can advantageously be selected from water, alcohols, ketones, esters, ethers, chlorinated solvents, polyols or mixtures of two or more aforementioned miscible solvents.
- a particular extract can be made for each plant or plant organ, depending on its properties, in order to optimize the extraction yield of the desired molecules or families of molecules.
- extract should be understood as "plant cell extract” belonging to the aforementioned group and more specifically as “cell extract of at least one plant” of the aforementioned group.
- Said plant can be obtained by in vitro culture or in vivo.
- in vitro culture is meant all of the techniques known to those skilled in the art that artificially allow the production of a plant or part of a plant.
- In vivo culture means all the cultivation techniques that make it possible to obtain a plant or a part of a plant.
- the extract may be an organ extract (root, stem, leaf, bark) or even organ cells, at least one plant of the genus Paeonia or Nymphaea, or an undifferentiated cell extract. at least one such plant.
- Example 1 relates to the liquid extraction, but other physicochemical methods can be employed, and for example extraction with supercritical CO 2 , alone or in mixture with a co-solvent. or the extraction technique based on wave radiation, such as microwaves or ultrasound.
- any method of extraction or purification known to those skilled in the art can be used in the invention.
- a first step the fresh, frozen or dry plant material is crushed in a cold aqueous solution, and in a second step, the aqueous solution is filtered which is finally sterilized.
- This aqueous solution corresponds to the extract, which can then be dried (for example by evaporation, atomization or lyophilization).
- the extract thus obtained can be evaporated to dryness, the residue being used as it is or after purification.
- Each extract can then be fractionated so as to enrich it with the desired active ingredient.
- the extracts used in the present invention can be made from all accessible parts of the plants.
- seed extracts are preferably used.
- the extracts of Paeonia suffruticosa and Nymphaea caerulea included in the compositions according to the present invention have shown, in the in vitro tests, described in greater detail below, a marked inhibitory power of the enzymes APN (aminopeptidase N) and NEP (neutral endopeptidase). .
- APN aminopeptidase N
- NEP neutral endopeptidase
- the extracts used in the compositions of the invention are generally of the order of 0.05 to 15.0%, preferably between 0.2 and 5%, for the extract of Nymphaea caerulea and of the order of 0. 0.5 to 5%, preferably from 0.1 to 3%, for the Paeonia suffruticosa extract, relative to the total weight of the composition.
- the extracts may be mixed to be incorporated in the composition and the amount of mixture used is generally between 0.05 and 20% by weight relative to the total weight of the composition.
- the ratio by weight of the extract of Paeonia suffruticosa to the Nymphaea caerulea extract is advantageously between 1: 1 and 1: 3, and preferably equal to 1: 2 or 1: 2.5.
- the concentration of each of the components in the composition may be selected depending on the intended use and the mode of administration. For prolonged protective treatment, lower doses, in the form of cream or gel dosed at approximately 1 to 5% (total of the two components), are preferably used. while a spot treatment may require higher doses, for example a serum dosed between 6 and 12%, where, preferably, the doses of extracts of Nymphaea caerulea and Paeonia suffruticosa are higher.
- these topical compositions can be used advantageously in dermatology and cosmetology for the treatment or prevention of itching sensations and topical pain.
- These compositions can be used daily, one to several times a day, without limitation of treatment time.
- compositions of the present invention are very well tolerated, they exhibit no phototoxicity and their application to the skin for prolonged periods of time does not imply any systemic effect.
- compositions according to the invention may contain, in addition to an extract of Paeonia suffruticosa and an extract of Nymphaea caerulea, secondary active agents which advantageously complement their activity, and which are compatible, that is to say not liable to react on each other or to mask or limit their respective effects.
- the complementary active ingredients are chosen for their action, for example for sun protection, anti-wrinkle effect, antiradical and antioxidant activity, anti-irritant activity, cellular nutrition, cellular respiration, hydration and cellular regeneration, anti-seborrhoeic treatments, as well as other active ingredients having an effect on the cutaneous tonicity.
- the secondary active agents may be chosen, for example, from a mimosa seed extract and a marigold seed extract favorably acting on the stimulation of neoformed collagens, Centella asiatica, a poppy extract, a marshmallow extract, cocoa polyphenols (preferably cocoa cells), hibiscus extract (Hibiscus abelmoschus), dill extract (Peucedaneum graveolens), monomethylsilanol, proline, or shea butter.
- a mimosa seed extract and a marigold seed extract favorably acting on the stimulation of neoformed collagens, Centella asiatica, a poppy extract, a marshmallow extract, cocoa polyphenols (preferably cocoa cells), hibiscus extract (Hibiscus abelmoschus), dill extract (Peucedaneum graveolens), monomethylsilanol, proline, or shea butter.
- compositions in accordance with the present invention may be presented in the galenical forms conventionally used for topical application. That is to say in the form of lotion, gel, emulsion (in particular cream or milk), biphasic emulsion oil-in-water or water-in-oil, triphasic emulsion, body oil, shampoo, hair lotion, mask, ointment, ointment, protective sticks for lips, nanocapsules, liposomes or transdermal patches, containing compatible and pharmaceutically acceptable excipients and carriers. They are preferably used in the form of cream, serum and gel.
- Topical administration are prepared by the usual techniques, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil-in-water emulsion, or conversely to prepare a water-in-oil emulsion.
- creams it is preferred to use lamellar structure emulsions containing little or no ethoxylated products.
- the cosmetic compositions according to the invention may also take the form of a lotion or solution in which the extracts are in encapsulated form.
- the microspheres according to the invention may for example consist of fatty substance, agar and water.
- the extracts can be incorporated into liposomes, glycosphers, chylomicrons, macro-, micro-, nano-particles as well as macro-, micro- and nanocapsules vectors and also be adsorbed onto powdery organic polymers, talcs , bentonites and other mineral supports.
- emulsions have good stability and can be stored for the time necessary for use at temperatures between 0 and 50 ° C without sedimentation of the constituents or phase separation.
- aqueous extract preferably with a hydroalcoholic extract.
- the topical compositions according to the invention may comprise excipients suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients.
- excipients suitable for external topical administration include in particular thickeners such as natural gums and synthetic polymers; gelling agents such as cellulose esters and carbopol; emollients and surfactants such as cetearyl octanoate, isopropyl myristate, cetearyl isononanoate, dimethicone, cyclomethicone, polyglyceryl 3-diisostearate, cetyl alcohol, cetyl palmitate; preservatives such as phenoxyethanol, methyl parahydroxybenzoate (methylparaben), ethyl parahydroxybenzoate (ethylparaben) and Phenonip® associating phenoxyethanol and parahydroxybenzoates; dyes; antibacterial agents, perfumes; etc.
- compositions of the invention are moisturizing agents such as propylene glycol, glycerine, butylene glycol, the sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols. It is also possible to add ultraviolet protection agents to the composition, and for example hydrophilic or lipophilic UV-A and UV-B sunscreens chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4.
- moisturizing agents such as propylene glycol, glycerine, butylene glycol, the sodium salt of pyrrolidone carboxylic acid (PCA sodium), and also antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
- antioxidant vitamins such as as vitamin E, for example tocopherol acetate or tocotrienol, vitamin C, natural polyphenols.
- UV protection agents for
- methoxy-benzophenone (Eusolex® 4360), or a cinnamic acid ester such as octyl methoxycinnamate (Eusolex® 2292), ethyl-2-hexyl methoxyninnamate (Parsol MCX®), or a cyano-, -diphenylacrylate such as octocrylene (Eusolex® OCR), 4-methylbenzylidene camphor (Eusolex 6300®), and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane (Eusolex 8020), and t- Butyl-methoxy dibenzoylmethane (Parsol 1789®). It is also possible to use anti-ultraviolet screen pigments, such as, for example, titanium dioxide, zinc oxide, zirconium oxide or aluminum oxide.
- anti-ultraviolet screen pigments such as, for example, titanium dioxide, zinc oxide,
- the cosmetic or dermopharmaceutical use of extracts includes all body and skin care products including sun, protective and tanning products, anti-aging, anti-seborrhoeic, tonic products ensuring the improvement of the appearance of the skin, including anti-acne treatment and redness of the skin.
- This example presents some experimental results of extraction on various selected plants.
- a - Paeonia suffruticosa extract A - Paeonia suffruticosa extract:
- the average yield is of the order of 15% B - Nymphaea caerulea extract:
- the aim of this study is to determine the inhibitory powers of plant extracts against metalloproteinases aminopeptidases N (APN) and neprilysin (NEP).
- APN metalloproteinases aminopeptidases N
- NEP neprilysin
- human soluble recombinant enzymes were used and their enzymatic activities evaluated using model Ala-B-naphthylamide substrates for APN and Suc-AAF-AMC for CIP.
- NEP and APN are proteases, their enzymatic activity can be measured using appropriate substrates.
- the most sensitive and most commonly used NEP assay is based on the Suc-Ala-Ala-Phe-AMC fluorogenic substrate (Spillantini et al., 1986, Yandle et al., 1992). NEP cleaves this substrate between Ala and Phe, and it is the addition of an excess of aminopeptidase N which releases the Phe residue and produces the AMC in fluorescent form. The fluorescence thus measured is proportional to the amount of enzyme present.
- the APN activity is measured using the chromogenic or fluorigenic substrates L-Leucine / Alanine-para-nitroanilide or L-Leucine / Alanine-B-naphthylamide. In both cases, the APN cleaves between the amino acid Leucine or Alanine releasing either the chromophore para-nitroanilide or the fluorophore B-naphthylamide (Chen et al., 1999).
- test conditions are as follows:
- test conditions are as follows:
- the active ingredient resulting from a 50/50 Paeonia / Nymphaea mixture thus produced has an inhibitory activity of the NEP and APN enzymes isolated with an IC50 of 36 mg / ml and 129 mg / ml, respectively.
- a cosmetic cream is prepared having the composition indicated below.
- Vegetable oils rosehip oil muscat / macadamia oil 4,5
- This cream is used once or twice a day by application to the areas of the skin to be treated.
- a serum is prepared having the weight composition indicated below.
- This serum can be used once or twice a day on the areas of the skin to be treated, possibly in addition to treatment with a cream.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1256091A FR2992561B1 (fr) | 2012-06-27 | 2012-06-27 | Composition topique apaisante a base d'extraits de paeonia et de nymphaea |
PCT/EP2013/063543 WO2014001465A2 (fr) | 2012-06-27 | 2013-06-27 | Composition topique apaisante a base d'extraits de paeonia et de nymphaea |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2866900A2 true EP2866900A2 (fr) | 2015-05-06 |
Family
ID=48699835
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13731825.9A Withdrawn EP2866900A2 (fr) | 2012-06-27 | 2013-06-27 | Composition topique apaisante a base d'extraits de paeonia et de nymphaea |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2866900A2 (fr) |
FR (1) | FR2992561B1 (fr) |
WO (1) | WO2014001465A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3062794B1 (fr) * | 2017-02-14 | 2021-11-26 | Sokhna Racky Ba | Procede de traitement cosmetique ternaire destine au sevrage progressif des peaux ayant subit une depigmentation volontaire tout en prevenant et corrigeant les signes du vieillissement. |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6468564B1 (en) | 1997-02-21 | 2002-10-22 | Clientele Beauty, Inc. | Topical compositions containing lotus for skin treatment |
JP2002121126A (ja) * | 2000-10-13 | 2002-04-23 | Noevir Co Ltd | 皮膚外用剤 |
WO2003045409A1 (fr) | 2001-11-29 | 2003-06-05 | Jiangsu Kanion Pharmaceutical Co., Ltd | Composition pharmaceutique produite a partir de medecine traditionnelle chinoise et son procede de production |
FR2835430A1 (fr) * | 2002-05-31 | 2003-08-08 | Oreal | Composition comprenant des nanocapsules enrobees de lecithine et un polymere d'acrylamide |
JP2004269382A (ja) | 2003-03-06 | 2004-09-30 | Shiseido Co Ltd | セリンプロテアーゼ阻害剤 |
EP1768684B1 (fr) | 2004-06-09 | 2012-05-23 | Laboratoire Nuxe | Composition comprenant un extrait de lotus bleu pour le traitement des contractions musculaires faciales incontrôlees |
JP2006124356A (ja) | 2004-11-01 | 2006-05-18 | Ichimaru Pharcos Co Ltd | インターロイキン−1α産生阻害剤 |
CN1977817A (zh) * | 2005-12-02 | 2007-06-13 | 上海莲氏轩生物工程有限公司 | 植物护理功能液 |
KR100787782B1 (ko) * | 2006-10-16 | 2007-12-21 | 주식회사 코리아나화장품 | 블루 로터스 추출물을 유효성분으로 함유하는 피부 자극완화용 화장료 조성물 |
KR20080098925A (ko) | 2007-05-08 | 2008-11-12 | (주)더페이스샵코리아 | 목단피 추출물을 함유하는 화장료 조성물 |
KR100946584B1 (ko) * | 2007-11-29 | 2010-03-09 | 주식회사 코리아나화장품 | 지실 추출물 및 블루로터스 추출물을 함유하는 수렴 및 피부 자극 완화용 화장료 조성물 |
CN101953483A (zh) * | 2009-07-20 | 2011-01-26 | 胡成爱 | 一种鲜花果粒南瓜汁 |
-
2012
- 2012-06-27 FR FR1256091A patent/FR2992561B1/fr active Active
-
2013
- 2013-06-27 EP EP13731825.9A patent/EP2866900A2/fr not_active Withdrawn
- 2013-06-27 WO PCT/EP2013/063543 patent/WO2014001465A2/fr active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2014001465A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014001465A2 (fr) | 2014-01-03 |
FR2992561B1 (fr) | 2015-09-18 |
WO2014001465A3 (fr) | 2014-02-27 |
FR2992561A1 (fr) | 2014-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR2814950A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP2691074A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
EP0946138A2 (fr) | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie | |
EP1768684B1 (fr) | Composition comprenant un extrait de lotus bleu pour le traitement des contractions musculaires faciales incontrôlees | |
FR3051369B1 (fr) | Extraits de faine de hetre, compositions et utilisations | |
EP2291173B1 (fr) | Association d'extraits de passiflore et d'anchuse utilisable en cosmetique | |
EP2699227B1 (fr) | Complexe d'extraits végétaux pour la protection de la peau. | |
WO2014001465A2 (fr) | Composition topique apaisante a base d'extraits de paeonia et de nymphaea | |
EP2811978B1 (fr) | Utilisation d'un extrait d'ecorce de pommier dans une composition cosmetique anti-age | |
EP2811977B1 (fr) | Utilisation d'un extrait de feuille de pommier dans une composition cosmetique pour le raffermissement de la peau | |
EP2777709B1 (fr) | Utilisation d'un extrait lipophile de jacinthe d'eau pour l'hydratation de la peau | |
FR2859102A1 (fr) | Utilisation d'un extrait de rhodiola crenulata par voie topique | |
FR2885300A1 (fr) | Composition topique pour la protection de l'epiderme | |
EP1879539B1 (fr) | Composition a base d'extraits de graines d'araucaria pour la protection de la peau | |
FR2885052A1 (fr) | Utilisation d'un extrait de maca pour proteger la microcirculation cutanee | |
FR2871382A1 (fr) | Composition comprenant un complexe d'extraits vegetaux, a effet decontractant de la peau | |
FR3099702A1 (fr) | Nouvelle utilisation cosmétique d’un extrait d’Epilobium angustifolium | |
FR3110421A1 (fr) | Extrait de Narcissus poeticus pour son utilisation cosmétique | |
FR3099701A1 (fr) | Nouvelle utilisation cosmétique d’une combinaison d’oenothéine-B et de quercétine-3-O-glucuronide | |
FR2885049A1 (fr) | Composition a base d'extraits de graines d'araucaria pour la protection de l'epiderme. | |
FR2871380A1 (fr) | Composition comprenant un extrait vegetal a effet decontractant de la peau | |
WO2012172200A1 (fr) | Composition a base de samanea saman pour la protection de la peau | |
FR2973695A1 (fr) | Composition a base de cafeine et de triacanthine pour le traitement des surcharges adipeuses. | |
WO2012140352A2 (fr) | Composition à base de gleditsia pour le traitement des surcharges adipeuses. | |
WO2013171202A2 (fr) | Utilisation d'un extrait de gattilier pour la preparation d'une composition cosmetique et/ou dermatologique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150106 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SOCIETE DE RECHERCHE COSMETIQUE SARL |
|
17Q | First examination report despatched |
Effective date: 20170119 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20170530 |